Ironwood Pharmaceuticals, Inc.
IRWDHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jun 2, 2026
Scan Results
Daily timeframeIronwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and. Valued at $569.6M, IRWD is a small-cap name in its sector. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Market Cap
$569.6M
Beta
0.30
P/E (TTM)
5.58
P/E (Fwd)
2.40
EPS (TTM)
$0.62
EPS (Fwd)
$1.44
ROE
—
ROA
33.1%
Cash
$220.5M
Total Debt
$597.4M
Free CF
$51.2M
52W Change
467.2%
Annual Financials
Cash vs Debt
The company holds $220.5M in cash, though total debt stands at $597.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $51.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on assets of 33.1% further supports the picture of efficient asset utilization. Revenue has pulled back from $410.6M (2022) to $296.2M (2025), a 28% decline worth watching.
With a beta below 0.7, Ironwood Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing IRWD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.